Glucosentient Inc.
Champaign, IL Doing business as Glucosentient
- UEI
- Z1GKW7XKS2P1
- CAGE
- 6LYL0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2109 S Oak St #100b, Champaign, IL 61820, USA
- Website
- glucosentient.com
- Founded
- 2011
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring… | National Institute of Allergy and Infectious Diseases | $265,773 | |
| A point-of-care salivary cytokine test for early detection of oral cancer - project summary / abstract oral cancer is… | National Institute of Dental and Craniofacial Research | $269,000 | |
| Rapid point-of-care test for hepatitis c virus (HCV) core antigen to screen active HCV infection - project summary /… | National Institute of Allergy and Infectious Diseases | $672,054 | |
| Assay optimization and adaptation for a customized meter development | National Institute of Allergy and Infectious Diseases | $1,408,787 | |
| Point-of-care assay using blood glucose meter for early warning of chronic lung rejection | National Heart Lung and Blood Institute | $225,000 |
About Glucosentient Inc.
Glucosentient Inc., doing business as Glucosentient, is a for-profit organization that specializes in developing innovative point-of-care diagnostic technologies for various medical applications. The company has been registered to receive federal awards since December 8, 2011, and has successfully secured multiple federal grant awards from agencies within the Department of Health and Human Services. Glucosentient's primary focus appears to be leveraging existing blood glucose meter (BGM) technology to create affordable, easy-to-use diagnostic platforms for a range of health conditions, particularly those relevant to global public health challenges.
Through its federal grant awards, Glucosentient has undertaken several significant research and development projects. The National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a $265,773 grant to develop a point-of-care therapeutic drug monitoring system for anti-tuberculosis drugs, aimed at improving treatment outcomes in resource-limited areas. The National Institute of Dental and Craniofacial Research (NIDCR) provided a $269,000 grant for the development of a salivary cytokine test for early detection of oral cancer, utilizing BGM technology to measure key biomarkers. Additionally, Glucosentient received funding from NIAID to create a rapid point-of-care test for hepatitis C virus core antigen, designed to screen for active HCV infections more efficiently than current two-step procedures. These projects demonstrate Glucosentient's commitment to addressing critical healthcare needs through innovative diagnostic solutions, particularly in the areas of infectious diseases and cancer detection.
Quick answers
What is Glucosentient Inc.'s UEI?
Glucosentient Inc.'s Unique Entity ID (UEI) in SAM.gov is Z1GKW7XKS2P1.
What is Glucosentient Inc.'s CAGE code?
Glucosentient Inc.'s CAGE code is 6LYL0.
What is Glucosentient Inc.'s primary NAICS code?
Glucosentient Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Glucosentient Inc. located?
Glucosentient Inc.'s physical address in SAM.gov is 2109 S Oak St #100b, Champaign, IL 61820, USA.
Is Glucosentient Inc. registered in SAM.gov?
Glucosentient Inc.'s SAM.gov registration expired on September 9, 2026.
What is Glucosentient Inc.'s most recent federal award?
Glucosentient Inc.'s most recent federal grant award is Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring… (R43AI181155), from National Institute of Allergy and Infectious Diseases, on February 12, 2024.
On GovTribe
See Glucosentient Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors